Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice (article)

Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice

Q24654670

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

Q27329126

Broad neutralization coverage of HIV by multiple highly potent antibodies

Q29615361

Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease

Q30554347

Early antibody therapy can induce long-lasting immunity to SHIV

Q33762877

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Q33786443

In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.

Q33796950

Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice

Q33930960

Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody

Q33990484

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

Q34180174

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

Q34204325

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Q34464133

Use of mutated self-cleaving 2A peptides as a molecular rheostat to direct simultaneous formation of membrane and secreted anti-HIV immunoglobulins

Q34500307

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Q34527469

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

Q34527478

Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen

Q34536677

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir

Q34583552

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

Q34593860

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

Q35076711

Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice

Q35112505

Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?

Q35595846

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

Q35641234

HIV-infected T cells are migratory vehicles for viral dissemination

Q36315429

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

Q36414891

Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice

Q36440069

Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs

Q36481483

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Q36961578

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

Q37145901

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

Q37236504

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Q37259407

Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy

Q37366489

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

Q37450695

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Q37624842

Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation

Q37661792

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

Q37708741

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

Q38742968

A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.

Q38843133

Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics

Q38882614

Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies

Q39579260

Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.

Q39691004

Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy.

Q40109869

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

Q40173380

Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies

Q40366328

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo

Q40631473

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

Q41019767

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

Q41933491

Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations

Q43890879

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Q44536209

A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates.

Q45873873

Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection

Q46318783

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells

Q47995100

Chimeric antigen receptor T-cell approaches to HIV cure

Q59359586

P433

issue

P407